Search
On the morning of June 30, 2026, Insilico Medicine made an announcement on the Hong Kong Stock Exchange. The company revealed that its Board Chairman, Executive Director, CEO, Chief Business Officer, and principal shareholder, Aleksandrs Zavoronkovs, along with Executive Director, CEO, and Chief Scientific Officer Ren Feng, have taken the initiative to prolong the lock-up period for all shares they currently possess by an extra six months, extending it until June 29, 2027. Specifically, Aleksandrs Zavoronkovs directly owns 42.5835 million shares, and Ren Feng has a beneficial interest in 8.7408 million shares. The initial lock-up period was scheduled to end on December 29, 2026. This voluntary extension is intended to uphold the stability of the company's stock price, bolster confidence in the capital markets, and protect the interests of shareholders.
-
C114 Communication Network -
Communication Home
